Fig. 4
From: CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma
CD22 iPS-CAR NK cells showed anti-tumor activity against CD22-positive ESCC cell lines in vitro. A CD22 expression in KYSE140 and KYSE150 was examined by flow cytometry. The majority of KYSE-140 and KYSE-150 cells had CD22 expression (red outline) compared with a control group (without primary antibody, blue outline). B Concentration-efficacy curve of iPS-NK-mediated killing of K562 cells. C CD22-CAR was not expressed in NK cells derived from iPS (iPS-NK) but expressed obviously in CD22-CAR-NK cells. D High CD22 expression in CD22-CAR-NK cells. E CD22-CAR-NK cells express specific NK cell markers, including CD16, CD45 and CD56. F Time-cell index curve of CD22-CAR-NK-mediated killing of KYSE140 cells. Data represent the mean ± SEM of ten independent experiments. ****p < 0.0001. G Time-cell index curve of CD22-CAR-NK cells killing KYSE150 cells. Data represent the mean ± SEM of ten independent experiments. ****p < 0.0001